Leflunomide:: new antirheumatic drug -: Effect on pregnancy outcomes

被引:0
|
作者
Kozer, E
Moretti, ME
Koren, G
机构
关键词
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
QUESTION I am treating a 34-year-old woman with rheumatoid arthritis. She began taking the new drug leflunomide (Arava (R)) 6 months ago and had good clinical response. She is now planning her first pregnancy. What should she do? ANSWER Leflunomide is a new and effective disease-modifying antirheumatic drug. Animal studies have shown an increased rate of malformations and fetal death in various species, but their are no data on pregnancy outcomes in humans treated with leflunomide. Since the drug has a prolonged and unpredictable elimination half-life, it should be stopped during pregnancy. The manufacturer recommends that patients who wish to become pregnant be treated with cholestyramine, which enhances elimination.
引用
收藏
页码:721 / 722
页数:2
相关论文
共 50 条
  • [21] INVESTIGATION INTO THE POLYMORPHISM OF A NEW NONSTEROIDAL ANTIRHEUMATIC DRUG
    KUTZ, G
    NURNBERG, E
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 1992, 38 (01) : 26 - 31
  • [22] PRINOMIDE - IMMUNOPHARMACOLOGICAL PROFILE OF A NEW ANTIRHEUMATIC DRUG
    DAVIS, P
    JOHNSTON, C
    INTERNATIONAL JOURNAL OF IMMUNOTHERAPY, 1990, 6 (01): : 61 - 70
  • [23] Effect of auranofin, an antirheumatic drug, on neutrophil apoptosis
    Liu, J
    Akahoshi, T
    Namai, R
    Matsui, T
    Kondo, H
    INFLAMMATION RESEARCH, 2000, 49 (09) : 445 - 451
  • [24] Effect of auranofin, an antirheumatic drug, on neutrophil apoptosis
    J. Liu
    T. Akahoshi
    R. Namai
    T. Matsui
    H. Kondo
    Inflammation Research, 2000, 49 : 445 - 451
  • [25] New Recommendations for antirheumatic Therapy in Pregnancy and Lactation Period
    Fischer-Betz, Rebecca
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2017, 76 (08): : 650 - 651
  • [26] Birth Outcomes in Women Who Have Taken Leflunomide During Pregnancy
    Chambers, Christina D.
    Johnson, Diana L.
    Robinson, Luther K.
    Braddock, Stephen R.
    Xu, Ronghui
    Lopez-Jimenez, Janina
    Mirrasoul, Nicole
    Salas, Elizabeth
    Luo, Yunjun J.
    Jin, Shelia
    Jones, Kenneth Lyons
    ARTHRITIS AND RHEUMATISM, 2010, 62 (05): : 1494 - 1503
  • [27] PREGNANCY OUTCOMES OF RHEUMATIC PATIENTS WITH PRE/PERI GESTATIONAL LEFLUNOMIDE EXPOSURE
    Karadag, O.
    Kilic, L.
    Erbil, A. A.
    Yilmaz, N.
    Akdogan, A.
    Kalyoncu, U.
    Bilgen, S. A.
    Kiraz, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 896 - 897
  • [28] Pregnancy outcomes in women exposed to DMARDS agents: The case of leflunomide.
    Chambers, C. D.
    Jones, K. L.
    Johnson, D. L.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2007, 25 (02) : 126 - 126
  • [29] EFFECT OF NEW ANTIRHEUMATIC DRUG ON INTERLEUKINS PRODUCTION FROM HUMAN MONONUCLEAR-CELLS
    TAKESHITA, K
    SUGIMOTO, T
    OTOMO, S
    AKABOSHI, T
    KASHIWAZAKI, S
    ARTHRITIS AND RHEUMATISM, 1992, 35 (09): : S309 - S309
  • [30] PHARMACOKINETICS IN RATS OF THE IMMUNOSUPPRESSIVE AND ANTIRHEUMATIC DRUG LEFLUNOMIDE MEASURED BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY (HPLC)
    HSIEH, GC
    ANDREWS, JM
    FEY, TA
    KRAUSE, RA
    BRETHEIM, PT
    MOLLISON, KW
    LULY, JR
    FASEB JOURNAL, 1995, 9 (04): : A946 - A946